Effects of fluoxetine on fish: What do we know and where should we focus our efforts in the future?

被引:23
|
作者
Correia, Daniela [1 ]
Domingues, Ines [1 ]
Faria, Melissa [2 ]
Oliveira, Miguel [1 ]
机构
[1] Univ Aveiro, Ctr Environm & Marine Studies CESAM, Dept Biol, Campus Univ Santiago, P-3810193 Aveiro, Portugal
[2] IDAEA CSIC, Jordi Girona 18, Barcelona 08034, Spain
关键词
SSRIs; Antidepressants; Serotonin; Effects; Environmental levels; SEROTONIN REUPTAKE INHIBITORS; ZEBRAFISH DANIO-RERIO; PHARMACEUTICAL POLLUTANT FLUOXETINE; SOLID-PHASE EXTRACTION; ENVIRONMENTALLY-RELEVANT CONCENTRATIONS; WASTE-WATER CONTAMINANTS; TRAP MASS-SPECTROMETRY; PERSONAL CARE PRODUCTS; SIAMESE FIGHTING FISH; ANTIDEPRESSANT FLUOXETINE;
D O I
10.1016/j.scitotenv.2022.159486
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Fluoxetine is one of the most studied and detected selective serotonin reuptake inhibitors in the aquatic environment, found at concentrations ranging from ng/L to mu g/L. Its presence in this environment can induce effects on aquatic or-ganisms that may compromise their fitness. Several experimental studies have demonstrated that fluoxetine can in-duce neurotoxicity, genetic and biochemical changes, and cause behavioral dysfunction in a wide range of fish species. However, contradictory results can be found. There is thus the need for a comprehensive review of the current state of knowledge on the effects of fluoxetine on fish at different levels of biological organization, highlighting inclu-sive patterns and discussing the potential causes for the contradictory results, that can be found in the available liter-ature. This review also aims to explore and identify the main gaps in knowledge and areas for future research. We conclude that environmentally relevant concentrations of fluoxetine (e.g., from 0.00345 mu g/L) produced adverse ef-fects and often this concentration range is not addressed in conventional environmental risk assessment strategies. Its environmental persistence and ionizable properties reinforce the need for standardized testing with representative aquatic models, targeting endpoints sensitive to the specific mode of action of fluoxetine, in order to assess and rank its actual environmental risk to aquatic ecosystems.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Where We Should Focus Green Chemistry Efforts
    Warner, John C.
    ALDRICHIMICA ACTA, 2015, 48 (01) : 29 - 29
  • [32] Vulvodynia: What We Know and Where We Should Be Going
    Havemann, Logan M.
    Cool, David R.
    Gagneux, Pascal
    Markey, Michael P.
    Yaklic, Jerome L.
    Maxwell, Rose A.
    Iyer, Ashvin
    Lindheim, Steven R.
    JOURNAL OF LOWER GENITAL TRACT DISEASE, 2017, 21 (02) : 150 - 156
  • [33] Productive effects of public works programs: What do we know? What should we know?
    Gehrke, Esther
    Hartwig, Renate
    WORLD DEVELOPMENT, 2018, 107 : 111 - 124
  • [34] Where Are We, and What Should We Do Now?
    Cutchin, Malcolm P.
    JOURNAL OF APPLIED GERONTOLOGY, 2009, 28 (01) : 3 - 4
  • [35] Bifurcation Disease What Do We Know, What Should We Do?
    Latib, Azeem
    Colombo, Antonio
    JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (03) : 218 - 226
  • [36] Cannabis and psychosis: what do we know and what should we do?
    Colizzi, Marco
    Murray, Robin
    BRITISH JOURNAL OF PSYCHIATRY, 2018, 212 (04) : 195 - 196
  • [37] Neighborhoods and Health: What Do We Know? What Should We Do?
    Roux, Ana V. Diez
    AMERICAN JOURNAL OF PUBLIC HEALTH, 2016, 106 (03) : 430 - 431
  • [38] Minimally Invasive Glaucoma Surgery: What Do We Know? Where Should We Go?
    Xin, Chen
    Wang, Huangzhou
    Wang, Ningli
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2020, 9 (05): : 1 - 10
  • [39] Self-regulation interventions - what do we know and where should we go?
    O'Carroll, Ronan E.
    HEALTH PSYCHOLOGY REVIEW, 2020, 14 (01) : 159 - 164
  • [40] Bone health and back pain: What do we know and where should we go?
    Briggs, A. M.
    Straker, L. M.
    Wark, J. D.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 (02) : 209 - 219